Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonicog alfa - Takeda

Next Previous
Drug Profile

Vonicog alfa - Takeda

Alternative Names: BAX 111; Recombinant von Willebrand factor; rVWF; SHP-677; TAK 577; VEYVONDI; VEYVONDI IU; Vonvendi

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Delbruck Center for Molecular Medicine
  • Developer Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Von Willebrand factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 06 Dec 2025 Pooled efficacy and adverse events data from two phase III trials in Von Willebrand disease presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-2025)
  • 13 Oct 2025 Phase-III clinical trials in Von Willebrand disease (Combination therapy) in China (IV) (NCT07129343)
  • 13 Oct 2025 Phase-III clinical trials in Von Willebrand disease (Treatment-experienced, Monotherapy) in China (IV) (NCT07129343)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top